Results 81 to 90 of about 5,159 (158)

PCSK9 inhibitor in acute ischemic stroke patient receiving mechanical thrombectomy: early outcomes and safety

Frontiers in Neurology
BackgroundLipid-lowering therapies are mainstays in reducing recurrence after acute ischemic stroke (AIS). Evolocumab, a Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, is a promising lipid-lowering agent known to decrease LDL ...
Jonguk Kim, Uichan Hong, Cindy W. Yoon, Jin Woo Bae, Joung-Ho Rha, Hee-Kwon Park   +5 more
doaj   +1 more source

Effects of evolocumab therapy and low LDL‐C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes

Endocrinology, Diabetes & Metabolism, 2020
Aims We assessed the change from baseline in vitamin E, steroid hormones, adrenocorticotropic hormone (ACTH), and gonadotropins, overall and by lowest achieved low‐density lipoprotein‐cholesterol (LDL‐C) level, in patients with type 2 diabetes and ...
Dirk J. Blom, Jiyan Chen, Zuyi Yuan, Joao L. C. Borges, Maria L. Monsalvo, Nan Wang, Andrew W. Hamer, Junbo Ge   +7 more
doaj   +1 more source

Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies

Cardiology and Therapy, 2019
Introduction The apolipoprotein A1 (apoA1) remnant ratio has been identified as an independent cardiovascular (CV) risk factor. Higher apoA1 remnant ratios may predict lower CV risk in some patients.
Heidi T. May, Joseph B. Muhlestein, Yuhui Ma, J. Antonio G. López, Blai Coll, John Nelson   +5 more
doaj   +1 more source

Evolocumab for early reduction of LDL-C levels in patients with acute ischemic stroke: a randomized controlled trial

Frontiers in Neurology
BackgroundLow-density lipoprotein cholesterol (LDL-C) has been determined as an established risk factor for acute ischemic stroke (AIS). Despite the recommendation for in-hospital initiation of high-intensity statin therapy in AIS patients, achieving the
Xiaohui Qiu, Yeyuan Liang, Yunfei Wei, Mengru Lu, Yujia Mei, Shiting Tang, Jian Tang, Jinyu Liang, Junli Liang   +8 more
doaj   +1 more source

Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis

Reviews in Cardiovascular Medicine
Background: Direct comparisons between the drugs are limited, and the dosing remains debatable. Therefore, the study aims to indirectly compare the efficacy and safety of inclisiran, alirocumab, evolocumab, and evinacumab in lipid ...
Lin Zhang, Bin Li, Wei Chen, Wei Li, Huayun Yang, Diguang Pan   +5 more
doaj   +1 more source

The use of evolocumab in the treatment of atherogenic dyslipidemia [PDF]

, 2023
The purpose of the study is to consider the efficacy and safety of evolocumab therapy on the example of a clinical case.Цель исследования – рассмотреть на примере клинического случая эффективность и безопасность терапии ...
Silakova, V. N., Smolenskaya, O. G., Силакова, В. Н., Смоленская, О. Г., Яковлева, Д. В., Yakovleva, D. V.   +5 more
core  

Asia–Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study

Cardiology and Therapy
Introduction Real-world data are needed to understand the effectiveness of new therapeutic options for low-density lipoprotein cholesterol (LDL-C) reduction in Asia–Pacific clinical practice.
Hung-Fat Tse, Hung-Yu Chang, David Colquhoun, Jung-Sun Kim, Kian Keong Poh, Karam Kostner, Pisit Hutayanon, Meejin Cho, Jeff Lange, Kamlanathan Kodiappan, Saikiran Leekha   +10 more
doaj   +1 more source

Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review

, 2018
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Evolocumab is fully human monoclonal antibody which binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), and prevents its blocking effect on recycling of ...
Kostic M., Tesic D., Jankovic, Slobodan, Anđelković J.   +3 more
core   +1 more source

Anti-PCSK9 Monotherapy for Hypercholesterolemia The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab

, 2014
ObjectivesThe aim of this study was to compare biweekly and monthly evolocumab with placebo and oral ezetimibe in patients with hypercholesterolemia in a phase III trial.BackgroundEvolocumab, a fully human monoclonal antibody against proprotein ...
Yang, Jingyuan, Lundqvist, Pernille, Neutel, Joel M., Wasserman, Scott M., Bays, Harold, Monsalvo, Maria Laura, Koren, Michael J., Kim, Jae B., Scott, Rob, Bolognese, Michael   +9 more
core   +1 more source

Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction

JACC: Basic to Translational Science
Summary: In a randomized trial with 55 participants from the EVACS (Evolocumab in Acute Coronary Syndrome) trials, patients with non–ST-segment elevation myocardial infarction (MI) or ST-segment elevation MI received a single dose of evolocumab or ...
Efthymios Ziogos, MD, Tarek Harb, MD, Ines Valenta, MD, Michael A. Vavuranakis, MD, PhD, Palmer L. Foran, BS, Marlene S. Williams, MD, Michael J. Blaha, MD, MPH, Allison G. Hays, MD, Steven R. Jones, MD, Thomas H. Schindler, MD, Steven P. Schulman, MD, Gary Gerstenblith, MD, Thorsten M. Leucker, MD, PhD   +12 more
doaj   +1 more source